Literature DB >> 19149699

The zebrafish as a novel tool for cardiovascular drug discovery.

John Rocke1, Julie Lees, Ian Packham, Timothy Chico.   

Abstract

The zebrafish is a well established model of vertebrate development, but has recently emerged as a powerful tool for cardiovascular research and in vivo cardiovascular drug discovery. The zebrafish embryo's low cost, small size and permeability to small molecules coupled with the ability to generate thousands of embryos per week, and improved automation of assays of cardiovascular development and performance allow drug screening for a number of cardiovascular effects. Such studies have already led to discovery of novel cardiovascular drugs with potentially clinically beneficial effects. In this review we summarise the advantages and disadvantages of the zebrafish for drug discovery using some patents, previous literature on zebrafish-based drug screening and assess where the zebrafish will fit into existing drug discovery programmes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19149699     DOI: 10.2174/157489009787260043

Source DB:  PubMed          Journal:  Recent Pat Cardiovasc Drug Discov


  10 in total

Review 1.  High-throughput screening and small animal models, where are we?

Authors:  Jean Giacomotto; Laurent Ségalat
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

2.  A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.

Authors:  Hui Cheng; Gabor Kari; Adam P Dicker; Ulrich Rodeck; Walter J Koch; Thomas Force
Journal:  Circ Res       Date:  2011-10-13       Impact factor: 17.367

3.  Whole plant based treatment of hypercholesterolemia with Crataegus laevigata in a zebrafish model.

Authors:  Robert M Littleton; Matthew Miller; Jay R Hove
Journal:  BMC Complement Altern Med       Date:  2012-07-23       Impact factor: 3.659

4.  Effects of cyanobacterial lipopolysaccharides from microcystis on glutathione-based detoxification pathways in the zebrafish (Danio rerio) embryo.

Authors:  Asha Jaja-Chimedza; Miroslav Gantar; Gregory D Mayer; Patrick D L Gibbs; John P Berry
Journal:  Toxins (Basel)       Date:  2012-05-25       Impact factor: 4.546

5.  Podocyte developmental defects caused by adriamycin in zebrafish embryos and larvae: a novel model of glomerular damage.

Authors:  Cristina Zennaro; Massimo Mariotti; Michele Carraro; Sara Pasqualetti; Alessandro Corbelli; Silvia Armelloni; Min Li; Masami Ikehata; Milan Clai; Mary Artero; Piergiorgio Messa; Giuliano Boscutti; Maria Pia Rastaldi
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

6.  Potential Molecular Mechanisms and Drugs for Aconitine-Induced Cardiotoxicity in Zebrafish through RNA Sequencing and Bioinformatics Analysis.

Authors:  Mingzhu Wang; Yanan Shi; Lei Yao; Qiang Li; Youhua Wang; Deyu Fu
Journal:  Med Sci Monit       Date:  2020-06-29

7.  Angiogenesis, Anti-Tumor, and Anti-Metastatic Activity of Novel α-Substituted Hetero-Aromatic Chalcone Hybrids as Inhibitors of Microtubule Polymerization.

Authors:  Moran Sun; Yuyang Wang; Minghua Yuan; Qing Zhao; Yixin Zhang; Yongfang Yao; Yongtao Duan
Journal:  Front Chem       Date:  2021-11-19       Impact factor: 5.221

8.  High-frequency ultrasound deformation imaging for adult zebrafish during heart regeneration.

Authors:  Chen Ho-Chiang; Hsin Huang; Chih-Chung Huang
Journal:  Quant Imaging Med Surg       Date:  2020-01

9.  The Efficacy of Puromycin and Adriamycin for Induction of Glomerular Failure in Larval Zebrafish Validated by an Assay of Glomerular Permeability Dynamics.

Authors:  Sebastien Andrew Rider; Finnius Austin Bruton; Richard George Collins; Bryan Ronald Conway; John James Mullins
Journal:  Zebrafish       Date:  2018-02-26       Impact factor: 1.985

10.  Anti-hypercholesterolemic Effect of Berbamine Isolated from Rhizoma Coptidis in Hypercholesterolemic Zebrafish Induced by High-Cholesterol Diet.

Authors:  Bing Han; Shuming Kou; Kai He; Yulong Han; Yue Wang; Tao Huang; Xia Zhou; Yubo Xiao; Xuegang Li; Xiaoli Ye
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.